Lee M. Krug, MD

As director of Memorial Sloan-Kettering's Mesothelioma Program, I head a multidisciplinary team of physicians and scientists dedicated to developing better treatment for the disease. Our group has led studies exploring the benefit of chemotherapy, surgery, and radiation for patients with early-stage mesothelioma. I have also led an international phase III trial of vorinostat for patients with mesothelioma who had previously been treated with chemotherapy.

I also direct the committee that establishes the National Comprehensive Cancer Network guidelines for the management of mesothelioma, and I serve as Chair of the Science Advisory Board for the Mesothelioma Applied Research Foundation. 

In addition, I am co-director of Memorial Sloan-Kettering's Medical Oncology/Hematology Fellowship Training Program.